Differential Effects of Genetically Determined Cholesterol Efflux Capacity on Coronary Artery Disease and Ischemic Stroke

Aoming Jin\textsuperscript{1,2†}, Mengxing Wang\textsuperscript{1,2†}, Weiqi Chen\textsuperscript{1,2}, Hongyi Yan\textsuperscript{1,2}, Xianglong Xiang\textsuperscript{1,2} and Yuesong Pan\textsuperscript{1,2*}

\textsuperscript{1}Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, \textsuperscript{2}China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Background: Observational studies indicated that cholesterol efflux capacity (CEC) of high-density lipoprotein (HDL) is inversely associated with cardiovascular events, independently of the HDL cholesterol concentration. The aim of the study is to examine the casual relevance of CEC for coronary artery disease (CAD) and myocardial infarction (MI), and compare it with that for ischemic stroke and its subtypes using a Mendelian randomization approach.

Methods: We performed a 2-sample Mendelian randomization to estimate the casual relationship of CEC with the risk of CAD, MI, and ischemic stroke. A CEC-related genetic variant (rs141622900) and other five genetic variants were used as the instrumental variables. Association of genetic variants with CAD were estimated in a GWAS involving 60,801 CAD cases and 123,504 controls. They were then compared with the associations of these variants with ischemic stroke and its subtypes (large vessel, small vessel, and cardioembolic) involving 40,585 ischemic stroke cases and 406,111 controls.

Results: Using the SNP of rs141622900 as the instrument, a 1-SD increase in CEC was associated with 45\% lower risk for CAD (odds ratio [OR] 0.55, 95\% confidence interval [CI] 0.44–0.69, \( p < 0.001 \)) and 33\% lower risk for MI (odds ratio [OR] 0.67, 95\% CI 0.52–0.87, \( p = 0.002 \)). By contrast, the causal effect of CEC was much weaker for ischemic stroke (odds ratio [OR] 0.79, 95\% CI 0.64–0.97, \( p = 0.02; p \) for heterogeneity = 0.03) and, in particular, for cardioembolic stroke (\( p \) for heterogeneity = 0.006) when compared with that for CAD. Results using five genetic variants as the instrument also indicated consistently weaker effects on ischemic stroke than on CAD.

Conclusion: Genetic predicted higher CEC may be associated with decreased risk of CAD. However, the casual association of CEC with ischemic stroke and specific subtypes would need to be validated in further Mendelian randomization studies.

Keywords: cholesterol efflux capacity, Mendelian randomization, coronary artery disease, stroke, genetics
INTRODUCTION

Epidemiologic studies have shown an inverse relationship between high-density lipoprotein (HDL) cholesterol levels and cardiovascular disease (1); however, recent clinical trials (2, 3) and Mendelian randomization (MR) studies (4, 5) failed to establish a clear causal association between HDL cholesterol and cardiovascular disease. This led to the hypothesis that the atheroprotective role of HDL lies in its function rather than in its concentrations (6).

The most important measure of HDL function is cholesterol efflux capacity (CEC), the ability of HDL to reverse cholesterol transport from peripheral cells (7). Previous cohort and case-control studies showed that CEC was inversely associated with atherosclerosis and the incidence of cardiovascular events in the general population, independently of the HDL cholesterol concentration (8–11). However, observational epidemiological studies may suffer from confounding and selection bias that represent obstacles to valid causal inference (12, 13). The causal association between CEC and cardiovascular diseases is still controversial. Furthermore, ischemic stroke had a heterogeneous mechanism and may have different cause and risk factors from coronary artery disease (CAD) (14). Previous MR studies have showed a weaker effect on ischemic stroke than on CAD for some lipid metabolic factors, such as low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 (PCSK9) variants (15, 16). Therefore, the relative effects of CEC on CAD and ischemic stroke needs further investigation.

MR study, using genetic variants as instrumental variables, is a method that can control potential confounders and reverse causation that may bias observational studies, and make stronger causal inferences between an exposure and risk of diseases (12). In the present study, we aimed to use MR analysis to examine the causal relevance of CEC for CAD and myocardial infarction (MI), and compares it with that for ischemic stroke and its subtypes.

MATERIALS AND METHODS

Study Design

A two-sample MR analysis using CEC-related genetic variants as instrumental variable was designed to evaluate the causal effect between CEC and CAD and ischemic stroke (Supplementary Figure 1). Summary-level data on the exposure (CEC) were derived from a recent published genome-wide association study (GWAS) of up to 5,293 European individuals (17) and data on the outcome (CAD and ischemic stroke) were obtained from GWAS of up to 446,696 European individuals (18, 19). Table 1 and Supplementary Table 1 shows the characteristics of these GWASs. Approval of ethics committee and written informed consent were obtained before data collection in the original GWASs.

Genetic Instrumental Variables

We used 6 single nucleotide polymorphisms (SNPs) associated with CEC identified through GWAS by Low-Kam et al. (17) as the instrumental variables. Low-Kam et al. (17) tested the genetic association between 4 CEC measures and genotypes at >9 million common autosomal DNA sequence variants in 5,293 French Canadians. They identified 10 genome-wide significant signals ($P < 6.25 \times 10^{-8}$) representing 7 loci. Among the 7 loci, 2 loci (near the PPP1CB/PLB1 and RBFOX3/ENPP7 genes) only reached genome-wide significance in the model further adjusted for HDL-C and triglyceride levels which may lead to false positive associations in the GWAS context (i.e., collider bias). Other 5 loci (CETP, LIPC, LPL, APOA1/C3/A4/A5, and APOE/C1/C2/C4) harbored genes with important roles in lipid biology and reached genome-wide significance in the model adjusted for sex, age squared, coronary artery disease status, experimental batches, statin treatment, and the first 10 principal components. Except for the APOE/C1/C2/C4 variant, association of other 4 loci disappeared when correcting for HDL-C and triglyceride levels. Only the SNP of rs141622900 in APOE/C1/C2/C4 locus reached genome-wide significance in both two models and was used as the instrument. In sensitivity analysis, we used the most significant SNP in each of the 5 loci (rs77069344, rs2070895, rs247616, rs964184, and rs445925) as the instrument. These 5 SNPs were in different genomic regions and not in linkage disequilibrium ($r^2 < 0.1$). The 1 SNP (rs141622900) instrument explained 0.9% and the 5 SNPs instrument explained 5.3% of the variance in CEC ($F$ statistic = 59.2 and 45.9, respectively, indicating sufficient strength of the instruments). Table 2 shows the characteristics and associations of these included SNPs with CEC.

Outcomes

Summary statistics for the association of each CEC-related SNP with the CAD and MI were extracted from the Coronary Artery Disease Genome-wide Replication And Meta-Analysis Plus Coronary Artery Disease Genetics (CARDioGRAMplusC4D) 1000 Genomes-based GWAS (17). The CARDioGRAMplusC4D 1000 Genomes-based GWAS interrogated 9.4 million variants in up to 60,801 CAD cases and 123,504 controls from 48 studies of predominantly European ancestry. Summary statistics for the association of the included SNPs with ischemic stroke and the 3 main subtypes of ischemic stroke (large artery stroke [LAS], small vessel stroke [SVS], cardioembolic stroke [CES]) were extracted from the GWAS of Multiancestry Genome-wide Association Study of Stroke (MEGASTROKE) consortium (19). The MEGASTROKE consortium tested ~8 million SNPs and indels with minor-allele frequency $\geq 0.01$ in up to 67,162 stroke cases and 454,450 controls from 29 studies, predominantly European ancestry (40,585 cases; 406,111 controls). This GWAS involved 34,217 cases with LAS, 5,386 cases with SVS and 7,193 cases with CES of European ancestry. The associations of the 6 individual SNPs for CEC with CAD and MI, and ischemic stroke and its subtypes are presented in Tables 3, 4, respectively.

Statistical Analysis

Per-allele effects of the selected SNPs on CEC and disease outcomes were extracted from the GWASs and used to estimate the causal effect of CEC on outcomes using two-sample MR analyses. Using the SNP of rs141622900 as the instrument, Wald ratio method were used to obtain effect estimate by dividing the SNP-outcome estimate by the SNP-CEC estimate. Standard error were estimated using the Delta method by dividing
TABLE 1 | Characteristics of the GWAS studies used in this study.

| Phenotype | Consortium | N | Ethnicity | Genotype data | PMID |
|-----------|------------|---|-----------|--------------|------|
| Exposure  |            |   |           |              |      |
| Cholesterol efflux capacity (CEC) | Up to 5,293 individuals | European | GWAS array | 30369316 |
| Outcomes  |            |   |           |              |      |
| Coronary artery disease (CAD) | CARDioGRAMplusC4D Up to 184,305 individuals | European | GWAS array | 26343387 |
| Myocardial infarction (MI) | CARDioGRAMplusC4D Up to 171,876 individuals | European | GWAS array | 26343387 |
| Ischemic stroke (IS) | MEGASTROKE Up to 446,696 individuals | European | GWAS array | 29531354 |
| Large artery stroke (LAS) | MEGASTROKE Up to 440,328 individuals | European | GWAS array | 29531354 |
| Small vessel stroke (SVS) | MEGASTROKE Up to 411,497 individuals | European | GWAS array | 29531354 |
| Cardioembolic stroke (CES) | MEGASTROKE Up to 413,304 individuals | European | GWAS array | 29531354 |

TABLE 2 | Characteristics of the included SNP loci associated with cholesterol efflux capacity.

| SNP       | Locus | Chromosome (Position) (hg19) | EA/OA | EAF | CEC          | Beta  | SE     | p          |
|-----------|-------|-----------------------------|-------|-----|--------------|-------|--------|------------|
| rs77069344 | LPL   | 8 (19,821,782)              | G/T   | 0.099 | J774 basal | 0.2008 | 0.0327 | 7.96 x 10^-10 |
| rs2070895  | LIPC  | 15 (58,723,939)             | A/G   | 0.230 | J774 basal | 0.1424 | 0.0232 | 8.49 x 10^-10 |
| rs247616   | CETP  | 16 (56,989,590)             | T/C   | 0.314 | J774 basal | 0.1466 | 0.0211 | 4.08 x 10^-12 |
| rs964184   | APOA1/C3/A4/A5 | 11 (116,648,917) | C/G   | 0.857 | J774 ABCA1 dependent | 0.2019 | 0.0281 | 6.78 x 10^-13 |
| rs445925   | APOE/C1/C2/C4 | 19 (45,415,640) | A/G   | 0.114 | J774 ABCA1 dependent | 0.2155 | 0.0303 | 1.20 x 10^-12 |
| rs141622900| APOE/C1/C2/C4 | 19 (45,426,792) | A/G   | 0.058 | BHK stimulated | 0.2833 | 0.0417 | 1.03 x 10^-11 |

SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effect allele frequency; CEC, cholesterol efflux capacity; SE, standard error. The unit of beta coefficients is log-odds per allele.

TABLE 3 | Genetic association of cholesterol efflux capacity related genetic variants with coronary artery disease and myocardial infarction in the CARDioGRAMplusC4D consortium.

| SNPs | EA/OA | Coronary artery disease Beta | SE | p     | Myocardial infarction Beta | SE | p     |
|------|-------|-------------------------------|----|-------|-------------------------------|----|-------|
| rs77069344 | G/T | -0.0514 | 0.0158 | 0.001 | -0.0651 | 0.0176 | 0.000 |
| rs2070895  | A/G | 0.0372 | 0.0108 | 0.001 | 0.0414 | 0.0121 | 0.001 |
| rs247616   | T/C | -0.0312 | 0.0103 | 0.002 | -0.0280 | 0.0114 | 0.014 |
| rs964184   | C/G | -0.0500 | 0.0124 | 0.000 | -0.0488 | 0.0139 | 0.000 |
| rs445925   | A/G | -0.0858 | 0.0187 | 0.000 | -0.0664 | 0.0214 | 0.002 |
| rs141622900| A/G | -0.1421 | 0.0278 | 0.000 | -0.0963 | 0.0315 | 0.002 |

EA, effect allele; OA, other allele; SE, standard error; SNP, single nucleotide polymorphism. The unit of beta coefficients is log-odds per allele. The odds ratio = exp(Beta), upper bound of odds ratio = exp(Beta+1.96 SE), and lower bound of odds ratio = exp(Beta-1.96 SE).

The above analysis was conducted in the UK Biobank GWAS and FinnGen GWAS as sensitivity analyses.

The percentage of variance explained in CEC was estimated by 2 x (effect on CEC) x minor allele frequency x (1 - minor allele frequency) (16). A power analysis was performed using a web-based application (https://sb452.shinyapps.io/power/). Effect estimates of CEC-outcome (CAD, MI, ischemic stroke and its subtypes) are presented as odds ratios (ORs) with their 95% confidence intervals (CIs) of outcome per 1-SD genetically higher CEC. To account for multiple testing, a Bonferroni-corrected significance level of $p < 0.0083$ (i.e., 0.05/6 for 6 outcomes) was used.
was predefined as statistically significant evidence for a causal association. All analyses were conducted with R 3.5.1 (R Development Core Team).

RESULTS

Genetically determined 1-SD increase in CEC was causally associated with a substantial decrease in risk of CAD (OR = 0.55, 95% CI: 0.44–0.69, \( p < 0.001 \)) and MI (OR = 0.67, 95% CI: 0.52–0.87, \( p = 0.002 \)); but, by contrast, was not causally associated with ischemic stroke (OR = 0.79, 95% CI: 0.64–0.97, \( p = 0.02 \)) or any separate subtype of ischemic stroke (LAS: OR = 0.67, 95% CI: 0.39–1.17, \( p = 0.16 \); SVS: OR = 1.08, 95% CI: 0.71–1.63, \( p = 0.73 \); CES: OR = 0.72, 95% CI: 0.44–1.17, \( p = 0.18 \)) at the Bonferroni-adjusted level of significance (\( p < 0.0083 \)) using the SNP of rs141622900 as the instrument (Figure 1). The effect of CEC on ischemic stroke was weaker than that on CAD (\( p \) for heterogeneity <0.001, \( I^2 = 93% \)) and MI (\( p \) for heterogeneity <0.001, \( I^2 = 91% \)), and in particular on CES (\( p \) for heterogeneity = 0.008, \( I^2 = 86% \); \( p \) for heterogeneity = 0.01, \( I^2 = 83% \)), whereas the effects of CEC on LAS and SVS were compatible with the magnitude of the effect observed for CAD (\( p \) for heterogeneity = 0.49 and 0.07, respectively) and MI (\( p \) for heterogeneity = 0.58 and 0.10, respectively). These analyses had a >99, 99, 42, and 53% power to detect a 10% decrease in risk of ischemic stroke, LAS, SVS, and CES (equivalent to the upper limit of the CI for MI and CAD, respectively); this can exclude a causal effect of CEC on ischemic stroke of the same magnitude as on CAD and MI, and indicate comparable effects of CEC on LAS, CAD, and MI.

Significant association for CAD and MI and insignificant association for ischemic stroke and its subtypes were also observed in sensitivity analyses using the MR-Egger, simple median and weighted median methods using the 5-SNPs instrument (Table 5). Evidence of heterogeneity was observed for the outcome of CAD and MI (\( Q = 42.5, p < 0.001; Q = 35.4, p < 0.001 \)) but not for the outcome of ischemic stroke or its subtypes (\( Q = 5.3, p = 0.26; Q = 6.6, p = 0.16; Q = 2.8, p = 0.59; Q = 2.0, p = 0.74 \)) in the IVW analysis. MR-Egger regression showed no evidence of directional pleiotropy for the association of CEC with all disease outcomes (all \( p \) value for intercept >0.05) (Table 5). In sensitivity analyses using FinnGen GWAS data, significant associations for ischemic heart disease and MI and insignificant association for ischemic stroke and CES were observed using the SNP of rs141622900 as the instrument. However, no significant associations for the outcomes was observed in the IVW analysis using the 5-SNPs instrument (Supplementary Table 2). In the multivariable MR adjusting for major causes of survival using the 5-SNPs instrument, the associations of CEC with ischemic stroke and its subtypes remained insignificant, which were similar to the estimates by the IVW method (Supplementary Table 3). Similar results of insignificant associations for ischemic stroke were observed in the UK Biobank data (Supplementary Table 4).

DISCUSSION

The present study is the first large-scale assessment and comparison of causal relevance of CEC and the risk of vascular
disease using Mendelian randomization approach. The results showed that genetic predicted higher CEC may be associated with decreased risk of CAD. However, the casual association of CEC with ischemic stroke and specific subtypes would need to be validated in further Mendelian randomization studies.

Our findings of inverse relationship between CEC and CAD and MI are consistent with several meta-analysis summarizing previous observational studies (10, 26, 27). Although results from the majority of studies were in line with the hypothesis that higher CEC is associated with lower risk of CAD (9, 11, 28–31), a study by Li showed that increased HDL-mediated CEC was paradoxically associated with increased risk for incident myocardial infarction or stroke, which based on the study population undergoing coronary angiography (32). Moreover, the German Diabetes Dialysis Study (4D Study) failed to observe an significant association of CEC with the composite outcome (cardiac death, nonfatal MI, and stroke) in patients with end-stage renal disease (33). The CEC was quantified using human THP-1-derived macrophage foam cells loaded with cholesterol, which was different from cAMP (cyclic adenosine monophosphate)-stimulated murine J774 macrophages employed by other studies in the general population (8, 11). The reasons for the apparent discrepancies among previous studies in the relationship between CEC and CAD are unclear but could be ascribed to difference in sample size, study population, study design, and methods for CEC measurements across studies. Considering the heterogeneity between observational studies and potential confounders that warrant caution, MR studies using genetic variants as instrumental variables could provide more robust evidence for the causal relationship of CEC and the health outcome of interest. The present study showed genetic predicted higher CEC was associated with lower CAD risk, which supports the direct causal association between CEC and CAD.

Our study does not support a causal role of CEC in ischemic stroke. Few studies have investigated the association between CEC and ischemic stroke and its subtypes expect two cohort studies with inconsistent results (9, 29). Results from the MESA (Multi-Ethnic Study of Atherosclerosis) cohort showed no relationship of cholesterol mass efflux capacity with stroke or with non-hemorrhagic stroke. However, a small subgroup (n = 37) of the Dallas Heart study reported an inverse association between CEC and stroke. Using genetic variants related to CEC as the instrument, the association between CEC and ischemic stroke was examined directly in our study. However, we found no evidence of significant causal relationships between CEC and ischemic stroke and its subtypes. In the present Mendelian randomization study, the estimates of CEC with ischemic stroke might be biased by sample selection on surviving exposure of interest and on surviving competing risk of the outcome (24). However, the results of multivariable MR analyses conducted by adjusting for potential causes of survival were consistent

### FIGURE 1 | Causal effect estimates of genetically predicted cholesterol efflux capacity on coronary artery disease and stroke. Estimates represented odds ratio (95% CI) per SD genetically higher cholesterol efflux capacity derived from Wald ratio method using rs141622900 as the instrument and inverse-variance weighted method using 5-SNPs (rs77069344, rs2070895, rs247616, rs964184, and rs445925) as the instrument. CI, confidence interval; SNP, single nucleotide polymorphism; CAD, coronary artery disease; MI, myocardial infarction; IS, ischemic stroke; LAS, large artery stroke; SVS, small vessel stroke; CES, cardioembolic stroke.
with the main results. As with any selection bias correction by multivariable adjustment, it may not be feasible to recover the valid estimate. We repeated the analyses in the UK Biobank data and FinnGen data, respectively. Both results were similar to the main results in the present study. Larger scale Mendelian randomization studies are still needed to clarify the genetic effects of CEC on ischemic stroke and assess any heterogeneity between ischemic stroke subtypes, which may shed light on the relationship of CEC on ischemic stroke further. Furthermore, in these future studies, the effects of genetically determined CEC on ischemic stroke could be compared between patients with vascular cognitive impairment vs. patients with non-cognitive impairment.

The HDL-mediated CEC is the ability to remove excess cholesterol from lipid-laden macrophages representing the first crucial step within the process of reverse cholesterol transport (7). Reverse cholesterol transport plays an important role in atheroprotective mechanism by facilitating the removal of cholesterol in the arterial wall and the subsequent decrease in the proinflammatory response (34, 35). Our study found that the effect of CEC was weaker on ischemic stroke than CAD, which were consistently observed in such comparisons in the effects of other blood lipid on vascular disease in recent Mendelian studies. A Mendelian study suggested that the effects of LDL cholesterol on ischemic stroke was weaker than that on coronary heart disease (16). Moreover, another Mendelian study showed PCSK9 genetic variants had smaller associations with risk of ischemic stroke than with risk of coronary heart disease (15). The potential explanation for the difference between the effects of CEC on CAD and ischemic stroke is the biological differences in these disease process. Ischemic stroke involves phenotypic heterogeneity, with different biological pathways for LAS, SVS, and CES, compared to the more homogenous CAD phenotype (36). Moreover, a review reported that hematological disorders were the most frequent etiology of cerebral infarcts of unusual cause (37). Except for the usual cerebrovascular risk factors such as hypertension, diabetes mellitus, and dyslipidemia, other newly factors could be considered of the causal relevance for ischemic stroke. Furthermore, differences in the distribution of risk factors as well as patient characteristics between CARDIoGRAMPlusC4D and METASTROKE consortium may partly explain the different effects for CAD and IS observed in the study. Additionally, insufficient statistical power due to small sample size, especially for stroke subtypes, may be considered as another reason. Anacetrapib, an CETP (cholesteryl ester transfer protein) inhibitor that was developed for increasing HDL cholesterol levels and promoting CEC to a greater degree, was shown a significant reduction in CAD in the REVEAL trial (38). Although it met its primary endpoint, the small improvement against the main goal and the safety of CETP inhibitor had become a point of contention consistently. Finally, Anacetrapib was not filed for approval with the US Food and Drug Administration. Our study provided supporting evidence for the causal relationship between CEC and risk of CAD, indicating potential intervention targets to the increase of CEC for improving cardiovascular outcomes.

The present Mendelian randomization analyses relies on three underlying assumptions. First, we identified 6 CEC-related SNPs ($P < 6.25 \times 10^{-9}$) served as instruments in the MR analysis that satisfied the first assumption. Second, we did not find that the 5-SNPs in the study were associated with other key lipids including low-density lipoprotein, triglycerides, total cholesterol, and apolipoprotein B based on GWAS datasets. And the results of multivariable MR analyses and sensitivity analyses using the UK Biobank data and FinnGen data were consistent with the main results. Thus, these results increase confidence in the validity of the second assumption that there is no confounding (measured or unmeasured) of the genetic variants with the outcome. Third, all the genetic variants were not directly associated with the outcomes ($all P > 5 \times 10^{-8}$), which suggested that the third assumption was not violated.

Our study has several limitations. First, the study was conducted based on datasets of predominantly European ancestry and generalization of the results to other populations of non-European ancestry was limited. However, the uniformity of the included subjects may minimize the risk of bias by population admixture. Second, the sample sizes of ischemic stroke subtypes were still relatively small, specifically for SVS and CES. Insignificant association between CEC and ischemic stroke subtypes could be attributed to insufficient statistical power. However, most estimates were consistent using different MR approaches, which suggests that the observed associations are not by chance. Third, although the GWAS that we used to identify all CEC-related SNPs represents the first and largest

### TABLE 5 | MR statistical sensitivity analyses using 5 SNPs as the instrumental variables.  

| Outcome | OR (95% CI) | P | Intercept (95% CI) | p value for intercept | OR (95% CI) | P | OR (95% CI) | p |
|---------|-------------|---|-------------------|----------------------|-------------|---|-------------|---|
| CAD (64,700/123,504) | 0.35 (0.14–0.89) | 0.03 | 0.156 (−0.007, 0.319) | 0.06 | 0.78 (0.71–0.86) | <0.001 | 0.79 (0.71–0.87) | <0.001 |
| MI (43,677/128,199) | 0.34 (0.13–0.89) | 0.03 | 0.161 (−0.004, 0.326) | 0.056 | 0.79 (0.70–0.88) | <0.001 | 0.79 (0.71–0.88) | <0.001 |
| IS (40,585/406,111) | 0.97 (0.57–1.65) | 0.92 | 0.008 (−0.083, 0.100) | 0.86 | 1.06 (0.96–1.17) | 0.26 | 1.06 (0.97–1.16) | 0.21 |
| LAS (34,217/406,111) | 1.60 (0.43–6.00) | 0.49 | −0.101 (−0.330, 0.128) | 0.39 | 0.89 (0.69–1.16) | 0.39 | 0.92 (0.72–1.17) | 0.49 |
| SVS (5,386/406,111) | 0.66 (0.26–1.64) | 0.37 | 0.074 (−0.086, 0.233) | 0.37 | 0.97 (0.78–1.19) | 0.74 | 0.96 (0.78–1.19) | 0.72 |
| CES (7,193/406,111) | 0.79 (0.38–1.71) | 0.55 | 0.048 (−0.086, 0.182) | 0.48 | 1.08 (0.90–1.28) | 0.41 | 1.08 (0.91–1.28) | 0.41 |

MR, mendelian randomization; OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; CAD, coronary artery disease; MI, myocardial infarction; IS, ischemic stroke; LAS, large artery stroke; SVS, small vessel stroke; CES, cardioembolic stroke. "Five SNPs in the instrument included rs77069344, rs2070895, rs247616, rs964184, and rs445925."
In establishing a claim of causality (trials. However, it cannot replace randomized controlled trials with a lot of advantages compared to randomized controlled trials. Recovering the valid estimates of CEC for ischemic stroke has not been fully addressed. Finally, Mendelian randomization has been considered as an alternative approach for causal inferences with a lot of advantages compared to randomized controlled trials. However, it cannot replace randomized controlled trials in establishing a claim of causality (39). Future clinical trials are still needed with sufficient statistical power to validate the causal relationship of CEC.

The study examined causal relationships between CEC and risk of vascular disease using MR analysis, and suggests that genetic predicted higher CEC may be associated with decreased risk of CAD. However, the causal association of CEC with ischemic stroke and specific subtypes would need to be validated in further Mendelian randomization studies.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

AJ and MW performed the study, analyzed the data, wrote the paper, and reviewed drafts of the paper. WC and XX wrote the paper and reviewed drafts of the paper. HY analyzed the data, prepared figures and tables, and reviewed drafts of the paper. YP conceived and designed the study, performed the study, analyzed the data, wrote the paper, and reviewed drafts of the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Natural Science Foundation of China (81971091 and 81901777), Beijing Hospitals Authority Youth Programme (QML20190501 and QML20200501), Young Elite Scientist Sponsorship Program from China Association for Science and Technology (2019QNRC001), Beijing Tiantan Hospital, Capital Medical University (2018-YQN-1 and 2020MP01) and Outstanding Young Talents Project of Capital Medical University (A2105).

**ACKNOWLEDGMENTS**

Data on cholesterol efflux capacity were derived from the GWAS performed by Low-Kam et al. Data on coronary artery disease/myocardial infarction have been contributed by CARDioGRAMplusC4D investigators and obtained from www.CARDIOGRAMPLUSC4D.ORG. Data on stroke have been contributed by MEGASTROKE investigators and obtained from http://megastroke.org. The MEGASTROKE project received funding from sources specified at http://megastroke.org/acknowledgements.html.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.891148/full#supplementary-material

**REFERENCES**

1. Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. *Circulation*. (2011) 124:2056–64. doi: 10.1161/CIRCULATIONAHA.111.028373
2. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. *BMJ*. (2014) 349:g4379. doi: 10.1136/bmj.g4379
3. Boekholdt SM,Arsenault BI, Hovingh GK, Mora S, Pedersen TR, Larosa JC, et al. Levels and changes of HDL cholesterol and apolipoprotein A-1 in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation*. (2013) 128:1504–12. doi: 10.1161/CIRCULATIONAHA.113.002670
4. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet*. (2012) 380:572–80. doi: 10.1016/S0140-6736(12)60312-2
5. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J*. (2015) 36:539–50. doi: 10.1093/eurheartj/ehu571
6. Anastasius M, Kockx M, Jessup W, Sullivan D, Rye KA, Kritharides L. Cholesterol efflux capacity: an introduction for clinicians. *Am Heart J*. (2016) 180:54–63. doi: 10.1016/j.ahj.2016.07.005
7. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. *Circulation*. (2012) 125:1905–19. doi: 10.1161/CIRCULATIONAHA.111.666589

8. Khra A, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke ME, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *N Engl J Med*. (2011) 364:127–35. doi: 10.1056/NEJMoa1001689

9. Rohatgi A, Khra A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. *N Engl J Med*. (2014) 371:2383–93. doi: 10.1056/NEJMoa1409965

10. Ye H, Xu G, Ren L, Peng J. Cholesterol efflux capacity in coronary artery disease: a meta-analysis. *Coron Artery Dis*. (2020) 31:642–9. doi: 10.1097/MCA.0000000000000886

11. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease: a prospective case-control study. *Lancet Diabetes Endocrinol*. (2015) 3:507–13. doi: 10.1016/S2213-8587(15)00216-6

12. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med*. (2008) 27:1133–63. doi: 10.1002/sim.3034

13. Baireinboim E, Pearl J. Causal inference and the data-fusion problem. *Proc Natl Acad Sci U S A*. (2016) 113:7345–52. doi: 10.1073/pnas.1510507113

14. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. *Circ Res*. (2017) 120:472–95. doi: 10.1161/CIRCRESAHA.116.380398

15. Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB; METASTROKE Collaboration of the ISGC. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. *Eur Heart J*. (2018) 39:354–9. doi: 10.1093/eurheartj/ehx373

16. Valdes-Marquez E, Parish S, Clarke R, Stari T, Worrall BB; METASTROKE KE. Association of HDL cholesterol efflux capacity with incident coronary artery disease. *Int J Epidemiol.* (2019)

17. Low-Kam C, Rhainds D, Lo KS, Barhdadi A, Boulé M, Alem S, et al. Variants at the APOE/C1/C2/C4 locus modulate cholesterol efflux capacity independently of high-density lipoprotein cholesterol. *J Am Heart Assoc*. (2018) 7:e009545. doi: 10.1161/JAHA.118.009545

18. Nikpay M, Ao M, Wu HH, Hall LM, Willenberg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. (2015) 47:1121–30. doi: 10.1038/ng.3396

19. Malik R, Chauhan G, Traylor M, Sargurunpremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*. (2018) 50:324–37. doi: 10.1038/s41588-018-0058-3

20. Thomas DC, Lawlor DA, Thompson JR. Re: estimation of bias in non genetic epidemiology. *Nat Genet*. (2017) 50:524–10. doi: 10.1038/ng.3396

21. Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. *Circ Res*. (2011) 114:205–13. doi: 10.1161/CIRCRESAHA.110.300760

22. Mendelson SJ, Prabhakaran S. Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review. *JAMA*. (2021) 325:1088–98. doi: 10.1001/jama.2020.26867

23. Arboix A, Jiménez C, Massons J, Parra O, Besses C. Hematological disorders: a commonly unrecognized cause of acute stroke. *Expert Rev Hematol*. (2016) 9:891–901. doi: 10.1080/17474086.2016.1208555

24. Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Mendelian randomization and the goal of inferring causation from observational studies in the vision sciences. *Ophthalmic Physiol Opt*. (2019) 39:11–25. doi: 10.1111/opo.12596

Conflict of Interest: *The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.*

Publisher's Note: *All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.*

Copyright © 2022 Jin, Wang, Chen, Yan, Xiang and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.